1
|
Dakhlaoui I, Maalej E, Martin H, Lucht A, Iriepa I, Moraleda I, Marco‐Contelles J, Chabchoub F, Ismaili L. Synthesis and Biological Assessment of PyrimidoTacrines as Promising Agents for Alzheimer's Disease Therapy. ChemistrySelect 2021. [DOI: 10.1002/slct.202102363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Imen Dakhlaoui
- Laboratoire de Chimie Appliquée: Hétérocycles Corps Gras et Polymères Faculté des Sciences de Sfax Université de Sfax. B. P 802.3000 Sfax Tunisie
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Emna Maalej
- Laboratoire Matériaux Traitement et Analyse (LMTA) Institut National de Recherche et d'Analyse Physico-chimique Technopole Ariana Tunisia
| | - Helene Martin
- PEPITE EA4267 Laboratoire de Toxicologie Cellulaire Univ. Bourgogne Franche-Comté F-25000 Besançon France
| | - Aurélia Lucht
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Isabel Iriepa
- Organic and Inorganic Chemistry Department. Ctra. Madrid-Barcelona, Km. 33, 6 University of Alcala 28871 Madrid Spain
| | - Ignacio Moraleda
- Organic and Inorganic Chemistry Department. Ctra. Madrid-Barcelona, Km. 33, 6 University of Alcala 28871 Madrid Spain
| | - Jose Marco‐Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC) Juan de la Cierva, 3 28006 Madrid Spain
| | - Fakher Chabchoub
- Laboratoire de Chimie Appliquée: Hétérocycles Corps Gras et Polymères Faculté des Sciences de Sfax Université de Sfax. B. P 802.3000 Sfax Tunisie
| | - Lhassane Ismaili
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| |
Collapse
|
2
|
Pérez-Bertólez S, Martín-Solé O, Moraleda I, Cuesta M, Massaguer C, Palazón P, Tarrado X. Advantages of endoscopic pilonidal sinus treatment. Cir Pediatr 2021; 34:191-199. [PMID: 34606699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Classic treatment of pilonidal sinus is associated with a high rate of complications and a long and painful postoperative period requiring daily wound care, with a decrease in patients' quality of life. The objective of our study was to evaluate the effectiveness and advantages of the endoscopic technique vs. conventional surgery of pilonidal sinus in the pediatric population. METHODS A quasi-experimental study was carried out in pediatric patients undergoing pilonidal sinus surgery at a single institution in 2019. Excision and healing by secondary intention (EHSI), excision and primary closure (EPC), and Pediatric Endoscopic Pilonidal Sinus Treatment (PEPSiT) were compared. The surgical technique chosen was surgeon-dependent. RESULTS 49 patients were studied - 14 undergoing PEPSiT, 23 undergoing EHSI, and 12 undergoing EPC. Full healing process was faster in PEPSiT than in EHSI (11 weeks earlier; 95% CI: 6.2-15.9; p < 0.001). Pain on the Visual Analogue Scale (VAS) and need for analgesics were less in the PEPSiT group (p = 0.001). Mean time to return to normal life was shorter with PEPSiT - 78 days earlier than EHSI (95% CI: 42.2-114.9; p < 0.001) and 39 days earlier than EPC (95% CI: -2.5-81.4; p = 0.06). No complications were recorded with PEPSiT, whereas complication rate with EHSI was 69.6%, and complication rate with EPC was 58.3% (p = 0.001). CONCLUSIONS Endoscopic pilonidal sinus treatment is effective, with a short and painless postoperative period, and easy wound care. It allows for an early return to normal life without restrictions.
Collapse
Affiliation(s)
- S Pérez-Bertólez
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - O Martín-Solé
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - I Moraleda
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - M Cuesta
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - C Massaguer
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - P Palazón
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| | - X Tarrado
- Pediatric Surgery Department. Sant Joan de Déu Hospital. University of Barcelona (Spain)
| |
Collapse
|
3
|
Pachón Angona I, Martin H, Daniel S, Moraleda I, Bonet A, Wnorowski A, Maj M, Jozwiak K, Iriepa I, Refouvelet B, Marco-Contelles J, Ismaili L. Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives. Int J Mol Sci 2020; 21:ijms21207652. [PMID: 33081112 PMCID: PMC7589057 DOI: 10.3390/ijms21207652] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 01/22/2023] Open
Abstract
We report herein the design, synthesis, biological evaluation, and molecular modelling of new inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), able to block Ca+2 channels also showing antioxidant and neuroprotective activities. The new MTDL, dialkyl 2,6-dimethyl-4-(4-((5-aminoalkyl)oxy)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3a-p, have been obtained via Hantzsch reaction from appropriate and commercially available precursors. Pertinent biological analysis has prompted us to identify MTDL 3h [dimethyl-4-(4-((5-(4-benzylpiperidin-1-yl)pentyl)oxy)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate] as an attractive inhibitor of AChE (1.8 μM) and BuChE (2 μM), Ca+2 channel antagonist (47.72% at 10 μM), and antioxidant (2.54 TE) agent, showing significant neuroprotection 28.68% and 38.29% against H2O2, and O/R, respectively, at 0.3 μM, thus being considered a hit-compound for further investigation in our search for anti-Alzheimer's disease agents.
Collapse
Affiliation(s)
- Irene Pachón Angona
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Helene Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Solene Daniel
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
| | - Alexandre Bonet
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva, 3, 28006-Madrid, Spain;
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| |
Collapse
|
4
|
García-Aparicio L, Blázquez-Gómez E, Martín Solé O, Rojas-Ticona J, Moraleda I, Tarrado X, Pérez-Bertólez S. Our experience with laparoscopic Anderson-Hynes ureteropyeloplasty. Cir Pediatr 2020; 33:131-136. [PMID: 32657097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
OBJECTIVE To analyze whether the application of laparoscopic surgery in the treatment of pyeloureteral junction obstruction (PUJO) has been beneficial for pediatric patients. MATERIALS AND METHODS Medical records of all patients undergoing PUJO surgery from January 1997 to December 2017 were retrospectively reviewed. Patients with <6-month follow-up and patients undergoing video-assisted surgery were excluded. Open surgery was compared with laparoscopic surgery. The following data were collected: surgical approach, need for and type of urinary diversion, operating time, mean hospital stay, complications, and restenosis rate. Ultrasound and diuretic renogram parameters were also retrieved. RESULTS 328 Anderson-Hynes pyeloplasties were analyzed, 142 of which had been performed laparoscopically. Overall success rate was 96.6%, and complication rate was 11.9%. No significant differences were noted between open and laparoscopic surgery. In 97.5% of surgeries, urine was diverted using an external nephroureteral catheter, a double J stent, or a Salle stent, with significant differences between open and laparoscopic surgery. Mean operating time was significantly longer in laparoscopic surgery. Mean hospital stay was significantly shorter in the laparoscopic surgery group. CONCLUSION Surgical approach does not play a role in PUJO surgery success. Therefore, in our view, laparoscopic surgery should be the technique of choice in pediatric patients.
Collapse
Affiliation(s)
- L García-Aparicio
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - E Blázquez-Gómez
- Anesthesiology Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - O Martín Solé
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - J Rojas-Ticona
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - I Moraleda
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - X Tarrado
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| | - S Pérez-Bertólez
- Pediatric Urology Unit. Pediatric Surgery Department. Sant Joan de Déu Hospital. Universitat de Barcelona (Spain)
| |
Collapse
|
5
|
Moraleda I, Oturan N, Saez C, Llanos J, Rodrigo MA, Oturan MA. A comparison between flow-through cathode and mixed tank cells for the electro-Fenton process with conductive diamond anode. Chemosphere 2020; 238:124854. [PMID: 31549676 DOI: 10.1016/j.chemosphere.2019.124854] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 09/10/2019] [Accepted: 09/13/2019] [Indexed: 06/10/2023]
Abstract
This work focusses on the production of hydrogen peroxide and in the removal of bromacil by the electro-Fenton process using two different electrochemical cells: mixed tank cell (MTC) and flow-through cell (FTC). Both cells use boron doped diamond (BDD) as anode and carbon felt as cathode to promote the formation of hydrogen peroxide. In the case of the MTC, two surface area ratios, Acathode/Aanode, have been used. Results show that the H2O2 produced by MTC and FTCPSC increases with the time until a stabilization state. For the FTCPSC, the average hydrogen peroxide concentration produced increases progressively with the current, while for MTC the maximum values are found in applying very low current densities. In addition, the FTCPSC provides higher concentrations of hydrogen peroxide for the same current density applied. Regarding the MTC, it can be stated that the higher the area of the cathode, the higher is the amount of H2O2 produced and the lower is the cell voltage (because of a more efficient current lines distribution). The initial oxidation of bromacil is very efficiently attained being rapidly depleted from wastewater. However, the higher production of hydrogen peroxide obtained by the FTCPSC cell does not reflect on a better performance of the electro-Fenton process. Thus, bromacil is better mineralized using the MTC cell with the lowest cathode area. This observation has been explained because larger concentrations of produced hydrogen peroxide seems to benefit the oxidation of intermediates and not the mineralization.
Collapse
Affiliation(s)
- I Moraleda
- University of Castilla-La Mancha, Chemical Engineering Department, Edificio Enrique Costa Novella. Campus Universitario s/n, 13005, Ciudad Real, Spain
| | - N Oturan
- Université Paris-Est, Laboratoire Géomatériaux et Environnement (LGE), UPEM, 77454, Marne-la-Vallée Cedex 2, France
| | - C Saez
- University of Castilla-La Mancha, Chemical Engineering Department, Edificio Enrique Costa Novella. Campus Universitario s/n, 13005, Ciudad Real, Spain
| | - J Llanos
- University of Castilla-La Mancha, Chemical Engineering Department, Edificio Enrique Costa Novella. Campus Universitario s/n, 13005, Ciudad Real, Spain
| | - M A Rodrigo
- University of Castilla-La Mancha, Chemical Engineering Department, Edificio Enrique Costa Novella. Campus Universitario s/n, 13005, Ciudad Real, Spain.
| | - M A Oturan
- Université Paris-Est, Laboratoire Géomatériaux et Environnement (LGE), UPEM, 77454, Marne-la-Vallée Cedex 2, France.
| |
Collapse
|
6
|
Pachón-Angona I, Refouvelet B, Andrýs R, Martin H, Luzet V, Iriepa I, Moraleda I, Diez-Iriepa D, Oset-Gasque MJ, Marco-Contelles J, Musilek K, Ismaili L. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:479-489. [PMID: 30712420 PMCID: PMC6366423 DOI: 10.1080/14756366.2018.1545766] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 10/21/2018] [Accepted: 11/04/2018] [Indexed: 12/13/2022] Open
Abstract
We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
Collapse
Affiliation(s)
- Irene Pachón-Angona
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Bernard Refouvelet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Rudolf Andrýs
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Helène Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, University Bourgogne Franche-Comté, Besançon, France
| | - Vincent Luzet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
| | - Daniel Diez-Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - María-Jesús Oset-Gasque
- Instituto de Investigación en Neuroquímica, Universidad Complutense de Madrid, Madrid, Spain
- Department of Biochemistry and Molecular Biology, School of Pharmacy, Plaza de Ramòn y Cajal, Madrid, Spain
| | | | - Kamil Musilek
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Lhassane Ismaili
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
7
|
Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de los Ríos C, Ismaili L. New Dual Small Molecules for Alzheimer’s Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition. J Med Chem 2019; 62:11416-11422. [DOI: 10.1021/acs.jmedchem.9b00937] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Rim Malek
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - Raquel L. Arribas
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Alejandra Palomino-Antolin
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Perle Totoson
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Celine Demougeot
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Tereza Kobrlova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | | | | | - Daniel Diez-Iriepa
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Justyna Godyń
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Dawid Panek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Malawska
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Monika Głuch-Lutwin
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Mordyl
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Agata Siwek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | | | - Javier Egea
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Cristóbal de los Ríos
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
| |
Collapse
|
8
|
Malek R, Refouvelet B, Benchekroun M, Iriepa I, Moraleda I, Andrys R, Musilek K, Marco-Contelles J, Ismaili L. Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer’s Disease Therapy. Curr Alzheimer Res 2019; 16:815-820. [DOI: 10.2174/1567205016666191011112624] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 07/10/2019] [Accepted: 08/16/2019] [Indexed: 01/18/2023]
Abstract
Background:
Many factors are involved in Alzheimer’s Disease (AD) such as amyloid
plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress. To counter the complexity of the
disease the new approach for drug development is to create a single molecule able to act simultaneously
on different targets.
Objective:
We conceived eight drug likeliness compounds targeting the inhibition of cholinesterases and
the scavenging of radicals.
Methods:
We synthesised the new molecules by the Passerini multicomponent reaction and evaluated
their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as well
as their antioxidant activities by the Oxygen Radical Absorbance Capacity (ORAC) assay. The lipinski’s
rule for drug likeness and in silico ADME prediction was also performed.
Results:
Compounds 4f [IC50 (EeAChE) = 0.30 μM; IC50 (eqBuChE) = 0.09 μM; ORAC = 0.64 TE]
and 4h [IC50 (EeAChE) = 1 μM; IC50 (eqBuChE) = 0.03 μM; ORAC = 0.50 TE] were identified as hits
for further development.
Conclusion:
The Passerini reaction allowed us the facile synthesis of ditarget molecules of interest for
the treatment of AD.
Collapse
Affiliation(s)
- Rim Malek
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Mohamed Benchekroun
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain
| | - Rudolf Andrys
- University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic
| | - Kamil Musilek
- University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva 3; 28006-Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| |
Collapse
|
9
|
Malek R, Maj M, Wnorowski A, Jóźwiak K, Martin H, Iriepa I, Moraleda I, Chabchoub F, Marco-Contelles J, Ismaili L. Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer’s disease therapy. Bioorg Chem 2019; 91:103205. [DOI: 10.1016/j.bioorg.2019.103205] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 07/19/2019] [Accepted: 08/14/2019] [Indexed: 11/17/2022]
|
10
|
Montanari S, Mahmoud AM, Pruccoli L, Rabbito A, Naldi M, Petralla S, Moraleda I, Bartolini M, Monti B, Iriepa I, Belluti F, Gobbi S, Di Marzo V, Bisi A, Tarozzi A, Ligresti A, Rampa A. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. Eur J Med Chem 2019; 178:243-258. [DOI: 10.1016/j.ejmech.2019.05.080] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 05/21/2019] [Accepted: 05/29/2019] [Indexed: 01/25/2023]
|
11
|
AlFadly ED, Elzahhar PA, Tramarin A, Elkazaz S, Shaltout H, Abu-Serie MM, Janockova J, Soukup O, Ghareeb DA, El-Yazbi AF, Rafeh RW, Bakkar NMZ, Kobeissy F, Iriepa I, Moraleda I, Saudi MN, Bartolini M, Belal AS. Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase. Eur J Med Chem 2019; 167:161-186. [DOI: 10.1016/j.ejmech.2019.02.012] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 02/04/2019] [Accepted: 02/04/2019] [Indexed: 12/31/2022]
|
12
|
Dgachi Y, Martin H, Malek R, Jun D, Janockova J, Sepsova V, Soukup O, Iriepa I, Moraleda I, Maalej E, Carreiras MC, Refouvelet B, Chabchoub F, Marco-Contelles J, Ismaili L. Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:163-170. [PMID: 30482062 PMCID: PMC6263107 DOI: 10.1080/14756366.2018.1538136] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
In view of the multifactorial nature of Alzheimer’s disease (AD), multitarget small molecules (MTSM) represent the most potent and attractive therapeutic strategy to design new drugs for Alzheimer’s disease therapy. The new MTSM KojoTacrines (KTs) were designed and synthesized by juxtaposition of selected pharmacophoric motifs from kojic acid and tacrine. Among them, 11-amino-2-(hydroxymethyl)-12-(3-methoxyphenyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano[2,3-b]quinolin-4(8H)-one (KT2d) was identified as less-hepatotoxic than tacrine, at higher concentration, a moderate, but selective human acetylcholinesterase inhibitor (IC50 = 4.52 ± 0.24 µM), as well as an antioxidant agent (TE = 4.79) showing significant neuroprotection against Aβ1–40 at 3 µM and 10 µM concentrations. Consequently, KT2d is a potential new hit-ligand for AD therapy for further biological exploration.
Collapse
Affiliation(s)
- Youssef Dgachi
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia.,b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Hélène Martin
- c Laboratoire de Toxicologie Cellulaire , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Rim Malek
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Daniel Jun
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Jana Janockova
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Vendula Sepsova
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Ondrej Soukup
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Isabel Iriepa
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Ignacio Moraleda
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Emna Maalej
- g Laboratoire Matériaux, Traitement et Analyse (LMTA) , Institut National de Recherche et d'Analyse Physico-chimique Technopole , Ariana-Tunis , Tunisia
| | - M Carmo Carreiras
- h Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy , Universidade de Lisboa , Lisboa , Portugal
| | - Bernard Refouvelet
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Fakher Chabchoub
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia
| | | | - Lhassane Ismaili
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| |
Collapse
|
13
|
Bautista-Aguilera ÓM, Budni J, Mina F, Medeiros EB, Deuther-Conrad W, Entrena JM, Moraleda I, Iriepa I, López-Muñoz F, Marco-Contelles J. Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile. J Med Chem 2018; 61:6937-6943. [PMID: 29969030 DOI: 10.1021/acs.jmedchem.8b00848] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Contilisant, a permeable, antioxidant, and neuroprotectant agent, showing high nM affinity at H3R and excellent inhibition of the monoamine oxidases and cholinesterases, is an affine and selective S1R agonist in the nanomolar range, based on the binding affinity and functional experiment, a result confirmed by molecular modeling. In addition, contilisant significantly restores the cognitive deficit induced by Aβ1-42 in the radial maze assay in an in vivo Alzheimer's disease test, comparing very favorably with donepezil.
Collapse
Affiliation(s)
| | - Josiane Budni
- Laboratório de Neurologia Experimental , Universidade do Extremo Sul Catarinense , Av. Universitária , 1105 Criciúma , Brazil
| | - Francielle Mina
- Laboratório de Neurologia Experimental , Universidade do Extremo Sul Catarinense , Av. Universitária , 1105 Criciúma , Brazil
| | - Eduarda Behenck Medeiros
- Laboratório de Neurologia Experimental , Universidade do Extremo Sul Catarinense , Av. Universitária , 1105 Criciúma , Brazil
| | - Winnie Deuther-Conrad
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research , Helmholtz-Zentrum Dresden-Rossendorf , 04318 Leipzig , Germany
| | - José M Entrena
- Animal Behavior Research Unit, Scientific Instrumentation Center , University of Granada , Parque Tecnológico de Ciencias de la Salud , 18100 Armilla , Granada , Spain
| | - Ignacio Moraleda
- Departamento de Química Orgánica and Química Inorgánica , Universidad de Alcalá , Ctra. Madrid-Barcelona, Km. 33,6 , 28871 Madrid , Spain
| | - Isabel Iriepa
- Departamento de Química Orgánica and Química Inorgánica , Universidad de Alcalá , Ctra. Madrid-Barcelona, Km. 33,6 , 28871 Madrid , Spain
| | - Francisco López-Muñoz
- Faculty of Health , Camilo José Cela University , 28692 Villanueva de la Cañada, Madrid , Spain
- Neuropsychopharmacology Unit , "Hospital 12 de Octubre" Research Institute , 28041 Madrid , Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, IQOG, CSIC , C/Juan de la Cierva 3 , 28006 Madrid , Spain
| |
Collapse
|
14
|
Chioua M, Buzzi E, Moraleda I, Iriepa I, Maj M, Wnorowski A, Giovannini C, Tramarin A, Portali F, Ismaili L, López-Alvarado P, Bolognesi ML, Jóźwiak K, Menéndez JC, Marco-Contelles J, Bartolini M. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. Eur J Med Chem 2018; 155:839-846. [PMID: 29958119 DOI: 10.1016/j.ejmech.2018.06.044] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Revised: 06/15/2018] [Accepted: 06/16/2018] [Indexed: 11/15/2022]
Abstract
Notwithstanding the combination of cholinesterase (ChE) inhibition and calcium channel blockade within a multitarget therapeutic approach is envisaged as potentially beneficial to confront Alzheimer's disease (AD), this strategy has been scarcely investigated. To explore this promising line, a series of 5-amino-4-aryl-3,4,6,7,8,9-hexahydropyrimido [4,5-b]quinoline-2(1H)-thiones (tacripyrimidines) (4a-l) were designed by juxtaposition of tacrine, a ChE inhibitor (ChEI), and 3,4-dihydropyrimidin-2(1H)-thiones, as efficient calcium channel blockers (CCBs). In agreement with their design, all tacripyrimidines, except the unsubstituted parent compound and its p-methoxy derivative, acted as moderate to potent CCBs with activities generally similar or higher than the reference CCB drug nimodipine and were modest-to-good ChEIs. Most interestingly, the 3'-methoxy derivative (4e) emerged as the first well balanced ChEI/CCB agent, acting as low micromolar hChEI (3.05 μM and 3.19 μM on hAChE and hBuChE, respectively) and moderate CCB (30.4% at 1 μM) with no significant hepatotoxicity toward HepG2 cells and good predicted oral absorption and blood brain barrier permeability.
Collapse
Affiliation(s)
- Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, 28006, Madrid, Spain
| | - Eleonora Buzzi
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, 28006, Madrid, Spain
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares, Madrid, Spain
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares, Madrid, Spain
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, Chodźki 4a, 20-093, Lublin, Poland
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, Chodźki 4a, 20-093, Lublin, Poland
| | - Catia Giovannini
- Department of Medical and Surgical Sciences, S.Orsola-Malpighi Hospital, CRBA, Via Massarenti, 9 40138, Bologna, Italy
| | - Anna Tramarin
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy
| | - Federica Portali
- Unidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040, Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, University Bourgogne Franche-Comté, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, 19, rue Ambroise Paré, F-25000, Besançon, France
| | - Pilar López-Alvarado
- Unidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040, Madrid, Spain
| | - Maria Laura Bolognesi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy
| | - Krzysztof Jóźwiak
- Department of Biopharmacy, Medical University of Lublin, Chodźki 4a, 20-093, Lublin, Poland
| | - J Carlos Menéndez
- Unidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040, Madrid, Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, 28006, Madrid, Spain.
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy.
| |
Collapse
|
15
|
Chioua M, Serrano E, Dgachi Y, Martin H, Jun D, Janockova J, Sepsova V, Soukup O, Moraleda I, Chabchoub F, Ismaili L, Iriepa I, Marco-Contelles J. Synthesis, Biological Assessment and Molecular Modeling of Racemic QuinoPyranoTacrines
for Alzheimer's Disease Therapy. ChemistrySelect 2018. [DOI: 10.1002/slct.201702781] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
| | - Estefanía Serrano
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - Youssef Dgachi
- Laboratory of Applied Chemistry: Heterocycles; Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax. B. P 802. 3000 Sfax-; Tunisia
| | - Hélène Martin
- PEPITE EA4267; Laboratoire de Toxicologie Cellulaire; Univ. Bourgogne Franche-Comté, F-; 25000 Besançon France
| | - Daniel Jun
- Department of Toxicology and Military Pharmacy; Faculty of Military Health Sciences; University of Defence; Hradec Kralove Czech Republic
| | - Jana Janockova
- Biomedical Research Center; University Hospital Hradec Kralove; Czech Republic
| | - Vendula Sepsova
- Department of Toxicology and Military Pharmacy; Faculty of Military Health Sciences; University of Defence; Hradec Kralove Czech Republic
| | - Ondrej Soukup
- Biomedical Research Center; University Hospital Hradec Kralove; Czech Republic
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles; Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax. B. P 802. 3000 Sfax-; Tunisia
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique; Neurosciences intégratives et cliniques EA 481; Univ. Franche-Comté; Univ. Bourgogne Franche-Comté; UFR SMP, 19, rue Ambroise Paré F-25000 Besançon France
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
| |
Collapse
|
16
|
Amariei G, Santiago-Morales J, Boltes K, Letón P, Iriepa I, Moraleda I, Fernández-Alba AR, Rosal R. Dendrimer-functionalized electrospun nanofibres as dual-action water treatment membranes. Sci Total Environ 2017; 601-602:732-740. [PMID: 28577408 DOI: 10.1016/j.scitotenv.2017.05.243] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Accepted: 05/26/2017] [Indexed: 06/07/2023]
Abstract
This work reports the preparation of composite electrospun membranes combining antimicrobial action with the capacity of retaining low-molecular weight non-polar pollutants. The membranes were electrospun blends of polyvinyl alcohol (PVA) and poly(acrylic acid) (PAA) stabilized using heat curing. The membranes were functionalized by grafting amino-terminated poly(amidoamine) (PAMAM) G3 dendrimers. The antimicrobial effect was assessed using strains of Escherichia coli and Staphylococcus aureus by tracking their capacity to form new colonies and their metabolic impairment upon contact with membranes. The antimicrobial activity was particularly high to the gram-positive bacterium S. aureus with a 3-log reduction in their capacity to colonize dendrimer-functionalized membranes with respect to neat PVA/PAA fibers. The effect to gram-positive bacteria was attributed to the interaction of dendrimers with the negatively charged bacterial membranes and resulted in membranes essentially free of bacterial colonization after 20h in contact with cultures at 36°C. The adsorption of toluene on PAA/PVA fibers and on dendrimer-functionalized membranes was assayed using toluene over a broad concentration range. The host-guest encapsulation of toluene inside dendrimer molecules was computed through docking studies, which allowed calculating a maximum capacity of 14 molecules of toluene per molecule of PAMAM G3. The theoretical prediction was in good agreement with the experimental capacity at the higher concentrations assayed.
Collapse
Affiliation(s)
- Georgiana Amariei
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Javier Santiago-Morales
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Karina Boltes
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Pedro Letón
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain
| | - Amadeo R Fernández-Alba
- Department of Analytical Chemistry, Agrifood Campus of International Excellence (ceiA3), European Union Reference Laboratory for Pesticide Residues in Fruit & Vegetables, University of Almeria, E-04010 Almería, Spain
| | - Roberto Rosal
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain.
| |
Collapse
|
17
|
Bautista‐Aguilera ÓM, Hagenow S, Palomino‐Antolin A, Farré‐Alins V, Ismaili L, Joffrin P, Jimeno ML, Soukup O, Janočková J, Kalinowsky L, Proschak E, Iriepa I, Moraleda I, Schwed JS, Romero Martínez A, López‐Muñoz F, Chioua M, Egea J, Ramsay RR, Marco‐Contelles J, Stark H. Multipotente Liganden mit kombinierter Cholinesterase‐ und Monoaminooxidase‐Inhibition sowie Histamin‐H
3
R‐Antagonismus bei neurodegenerativen Erkrankungen. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201706072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Óscar M. Bautista‐Aguilera
- Laboratorio de Química Médica Instituto de Química Orgánica General CSIC and Centro de Química Orgánica “Lora-Tamayo”, CSIC C/ Juan de la Cierva 3 28006 Madrid Spanien
| | - Stefanie Hagenow
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf Universitätsstrasse 1 40225 Düsseldorf Deutschland
| | - Alejandra Palomino‐Antolin
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica Hospital Universitario de la Princesa Calle de Diego de León, 62 28006 Madrid Spanien
| | - Víctor Farré‐Alins
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica Hospital Universitario de la Princesa Calle de Diego de León, 62 28006 Madrid Spanien
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481 Université Bourgogne Franche-Comté Rue Ambroise Paré 25000 Besançon Frankreich
| | - Pierre‐Louis Joffrin
- Biomedical Sciences Research Complex University of St Andrews, Biomolecular Sciences Building North Haugh St Andrews KY16 9ST Großbritannien
| | - María L. Jimeno
- Laboratorio de Química Médica Instituto de Química Orgánica General CSIC and Centro de Química Orgánica “Lora-Tamayo”, CSIC C/ Juan de la Cierva 3 28006 Madrid Spanien
| | - Ondřej Soukup
- Centrum biomedicínského výzkumu Fakultní nemocnice Hradec Králové Sokolska 581 50005 Hradec Kralove Tschechische Republik
| | - Jana Janočková
- Centrum biomedicínského výzkumu Fakultní nemocnice Hradec Králové Sokolska 581 50005 Hradec Kralove Tschechische Republik
| | - Lena Kalinowsky
- Institut für Pharmazeutische Chemie Goethe Universität Frankfurt Max-von-Laue-Strasse 9 60438 Frankfurt Deutschland
| | - Ewgenij Proschak
- Institut für Pharmazeutische Chemie Goethe Universität Frankfurt Max-von-Laue-Strasse 9 60438 Frankfurt Deutschland
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica Universidad de Alcalá Ctra. Madrid-Barcelona, Km. 33,6 28871 Madrid Spanien
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica Universidad de Alcalá Ctra. Madrid-Barcelona, Km. 33,6 28871 Madrid Spanien
| | - Johannes S. Schwed
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf Universitätsstrasse 1 40225 Düsseldorf Deutschland
| | - Alejandro Romero Martínez
- Departamento de Toxicología y Farmacología Facultad de Veterinaria, UCM Av. Puerta de Hierro, s/n 28040 Madrid Spanien
| | - Francisco López‐Muñoz
- Universidad Camilo José Cela C/ Castillo de Alarcón, 49 28692 Villanueva de la Cañada Madrid Spanien
| | - Mourad Chioua
- Laboratorio de Química Médica Instituto de Química Orgánica General CSIC and Centro de Química Orgánica “Lora-Tamayo”, CSIC C/ Juan de la Cierva 3 28006 Madrid Spanien
| | - Javier Egea
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica Hospital Universitario de la Princesa Calle de Diego de León, 62 28006 Madrid Spanien
| | - Rona R. Ramsay
- Biomedical Sciences Research Complex University of St Andrews, Biomolecular Sciences Building North Haugh St Andrews KY16 9ST Großbritannien
| | - José Marco‐Contelles
- Laboratorio de Química Médica Instituto de Química Orgánica General CSIC and Centro de Química Orgánica “Lora-Tamayo”, CSIC C/ Juan de la Cierva 3 28006 Madrid Spanien
| | - Holger Stark
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf Universitätsstrasse 1 40225 Düsseldorf Deutschland
| |
Collapse
|
18
|
Bautista-Aguilera ÓM, Hagenow S, Palomino-Antolin A, Farré-Alins V, Ismaili L, Joffrin PL, Jimeno ML, Soukup O, Janočková J, Kalinowsky L, Proschak E, Iriepa I, Moraleda I, Schwed JS, Romero Martínez A, López-Muñoz F, Chioua M, Egea J, Ramsay RR, Marco-Contelles J, Stark H. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H 3 R Antagonism for Neurodegenerative Diseases. Angew Chem Int Ed Engl 2017; 56:12765-12769. [PMID: 28861918 DOI: 10.1002/anie.201706072] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 07/27/2017] [Indexed: 11/06/2022]
Abstract
The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs). Novel indole derivatives with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs. These small-molecule hits demonstrated balanced activities at the targets, mostly in the nanomolar concentration range. Additional in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier. With this promising in vitro profile, contilisant (at 1 mg kg-1 i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.
Collapse
Affiliation(s)
- Óscar M Bautista-Aguilera
- Laboratorio de Química Médica, Instituto de Química Orgánica General, CSIC and Centro de Química Orgánica "Lora-Tamayo", CSIC, C/ Juan de la Cierva 3, 28006, Madrid, Spain
| | - Stefanie Hagenow
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| | - Alejandra Palomino-Antolin
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Calle de Diego de León, 62, 28006, Madrid, Spain
| | - Víctor Farré-Alins
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Calle de Diego de León, 62, 28006, Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Université Bourgogne Franche-Comté, Rue Ambroise Paré, 25000, Besançon, France
| | - Pierre-Louis Joffrin
- Biomedical Sciences Research Complex, University of St Andrews, Biomolecular Sciences Building, North Haugh, St Andrews, KY16 9ST, UK
| | - María L Jimeno
- Laboratorio de Química Médica, Instituto de Química Orgánica General, CSIC and Centro de Química Orgánica "Lora-Tamayo", CSIC, C/ Juan de la Cierva 3, 28006, Madrid, Spain
| | - Ondřej Soukup
- Centrum biomedicínského výzkumu, Fakultní nemocnice Hradec Králové, Sokolska 581, 50005, Hradec Kralove, Czech Republic
| | - Jana Janočková
- Centrum biomedicínského výzkumu, Fakultní nemocnice Hradec Králové, Sokolska 581, 50005, Hradec Kralove, Czech Republic
| | - Lena Kalinowsky
- Institut für Pharmazeutische Chemie, Goethe Universität Frankfurt, Max-von-Laue-Strasse 9, 60438, Frankfurt, Germany
| | - Ewgenij Proschak
- Institut für Pharmazeutische Chemie, Goethe Universität Frankfurt, Max-von-Laue-Strasse 9, 60438, Frankfurt, Germany
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Madrid, Spain
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Madrid, Spain
| | - Johannes S Schwed
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| | - Alejandro Romero Martínez
- Departamento de Toxicología y Farmacología, Facultad de Veterinaria, UCM, Av. Puerta de Hierro, s/n, 28040, Madrid, Spain
| | - Francisco López-Muñoz
- Universidad Camilo José Cela, C/ Castillo de Alarcón, 49, 28692, Villanueva de la Cañada, Madrid, Spain
| | - Mourad Chioua
- Laboratorio de Química Médica, Instituto de Química Orgánica General, CSIC and Centro de Química Orgánica "Lora-Tamayo", CSIC, C/ Juan de la Cierva 3, 28006, Madrid, Spain
| | - Javier Egea
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Calle de Diego de León, 62, 28006, Madrid, Spain
| | - Rona R Ramsay
- Biomedical Sciences Research Complex, University of St Andrews, Biomolecular Sciences Building, North Haugh, St Andrews, KY16 9ST, UK
| | - José Marco-Contelles
- Laboratorio de Química Médica, Instituto de Química Orgánica General, CSIC and Centro de Química Orgánica "Lora-Tamayo", CSIC, C/ Juan de la Cierva 3, 28006, Madrid, Spain
| | - Holger Stark
- Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany
| |
Collapse
|
19
|
Amariei G, Boltes K, Letón P, Iriepa I, Moraleda I, Rosal R. Poly(amidoamine) dendrimers grafted on electrospun poly(acrylic acid)/poly(vinyl alcohol) membranes for host-guest encapsulation of antioxidant thymol. J Mater Chem B 2017; 5:6776-6785. [PMID: 32264327 DOI: 10.1039/c7tb01498h] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Amino-terminated fifth generation poly(amidoamine) (PAMAM G5-NH2) dendrimers were grafted onto the surface of poly(acrylic acid)/poly(vinyl alcohol) (PAA/PVA) electrospun fibres with the purpose of creating a host-guest architecture for the controlled delivery of a natural antioxidant, thymol. The nanofibers were stabilized by esterification crosslinking to produce a water insoluble non-woven membrane. The functionalization with PAMAM G5-NH2 led to dendrimer loadings in the 7.4 × 10-7-2.25 × 10-6 mol dendrimer per g membrane range. The resulting materials were characterized using SEM, ATR-FTIR and surface ζ-potential measurements. The loading capacity for thymol reached 2.5 × 10-4 mol thymol per g membrane. The membranes were tested for thymol release in different aqueous and non-aqueous food simulants. Computational modelling was used to get a further insight into the host-guest association of thymol and PAMAM G5-NH2 molecules through docking studies. For this purpose, we examined the molecular level details of the dendrimer-guest complex, calculated the number of included or attached molecules, the exact location of thymol in host-guest complexes and the local environment around the thymol molecules. Docking studies showed that PAMAM-G5-NH2 dendrimers can encapsulate thymol molecules through hydrophobic interactions and hydrogen bonding. The maximum amount of thymol molecules theoretically encapsulated was 16, while another 25 could be hosted at the dendrimer surface through interaction with the outer part or the dendritic branches. The experimental value was 37 ± 5, in agreement with theoretical predictions.
Collapse
Affiliation(s)
- Georgiana Amariei
- Department of Chemical Engineering, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
20
|
Wang L, Moraleda I, Iriepa I, Romero A, López-Muñoz F, Chioua M, Inokuchi T, Bartolini M, Marco-Contelles J. 5-Methyl- N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5 H-indolo[2,3- b]quinolin-11-amine: a highly potent human cholinesterase inhibitor. Medchemcomm 2017; 8:1307-1317. [PMID: 30108842 PMCID: PMC6071787 DOI: 10.1039/c7md00143f] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 04/26/2017] [Indexed: 12/13/2022]
Abstract
The synthesis, cholinesterase inhibition, molecular modelling and ADME properties of novel tacrine-neocryptolepine heterodimers are described. Compound 3 [5-methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine], showing a moderate inhibition of the Aβ1-42 self-aggregation (26.5% at a 1 : 5 ratio with Aβ1-42), and a calculated log BB value (0.27) indicating excellent potential BBB penetration, is a highly potent human cholinesterase inhibitor [IC50 (hAChE) = 0.95 ± 0.04 nM; IC50 (hBuChE) = 2.29 ± 0.14 nM] which can be listed among the most potent hAChE inhibitors so far identified, and is not hepatotoxic in vitro at the concentrations at which the ChEs are inhibited. A molecular modeling study was also undertaken in order to elucidate the AChE and the BuChE bind modes of all the new compounds. The docking results show that all of them bind to AChE in extended conformations and to BuChE in folded conformations. Moreover, these studies revealed that the length of the linker is crucial to binding both the catalytic anionic site and the peripheral anionic site.
Collapse
Affiliation(s)
- Li Wang
- Division of Chemistry and Biotechnology , Graduate School of Natural Science and Technology , Okayama University , 3.1.1 Tsushima-Naka, Kita-ku , Okayama 700-8530 , Japan . ; Tel: +81 86 294 5045
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica , Universidad de Alcalá , Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares , Madrid , Spain
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica , Universidad de Alcalá , Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares , Madrid , Spain
| | - Alejandro Romero
- Departamento de Toxicología y Farmacología , Facultad de Veterinaria , Universidad Complutense de Madrid , 28040-Madrid , Spain
| | - Francisco López-Muñoz
- Faculty of Health , Camilo José Cela University , C/Castillo de Alarcón, 49; 28692 Villanueva de la Cañada , Madrid , Spain
- Neuropsychopharmacology Unit , "Hospital 12 de Octubre" Research Institute , Av. de Córdoba s/n , 28041 Madrid , Spain
| | - Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC) , C/ Juan de la Cierva 3 , 28006-Madrid , Spain . ; Tel: +34 91 5622900
| | - Tsutomu Inokuchi
- Division of Chemistry and Biotechnology , Graduate School of Natural Science and Technology , Okayama University , 3.1.1 Tsushima-Naka, Kita-ku , Okayama 700-8530 , Japan . ; Tel: +81 86 294 5045
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology , Alma Mater Studiorum , University of Bologna , Via Belmeloro 6 , 40126 Bologna , Italy . ; Tel: +39 0512099729
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC) , C/ Juan de la Cierva 3 , 28006-Madrid , Spain . ; Tel: +34 91 5622900
| |
Collapse
|
21
|
García-Font N, Hayour H, Belfaitah A, Pedraz J, Moraleda I, Iriepa I, Bouraiou A, Chioua M, Marco-Contelles J, Oset-Gasque MJ. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease. Eur J Med Chem 2016; 118:178-92. [DOI: 10.1016/j.ejmech.2016.04.023] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 04/06/2016] [Accepted: 04/08/2016] [Indexed: 11/30/2022]
|
22
|
Boulebd H, Ismaili L, Bartolini M, Bouraiou A, Andrisano V, Martin H, Bonet A, Moraleda I, Iriepa I, Chioua M, Belfaitah A, Marco-Contelles J. Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy. Molecules 2016; 21:400. [PMID: 27023499 PMCID: PMC6273229 DOI: 10.3390/molecules21040400] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 03/11/2016] [Accepted: 03/15/2016] [Indexed: 12/03/2022] Open
Abstract
Herein we describe the synthesis and in vitro biological evaluation of thirteen new, racemic, diversely functionalized imidazo pyranotacrines as non-hepatotoxic, multipotent tacrine analogues. Among these compounds, 1-(5-amino-2-methyl-4-(1-methyl-1H-imidazol-2-yl)-6,7,8,9-tetrahydro-4H-pyrano[2,3-b]quinolin-3-yl)ethan-1-one (4) is non-hepatotoxic (cell viability assay on HepG2 cells), a selective but moderately potent EeAChE inhibitor (IC50 = 38.7 ± 1.7 μM), and a very potent antioxidant agent on the basis of the ORAC test (2.31 ± 0.29 μmol·Trolox/μmol compound).
Collapse
Affiliation(s)
- Houssem Boulebd
- Equipe de Synthèse de Molécules à Objectif Thérapeutique, Laboratoire des Produits Naturels d'Origine Végétale et de Synthèse Organique (PHYSYNOR), Université des frères Mentouri, Campus de Chaabat-Ersas, Constantine 25000, Algeria.
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481, UFR SMP, Univ. Franche-Comté, Univ. Bourgogne Franche-Comté, 19, rue Ambroise Paré, F-Besançon 25000, France.
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, Bologna 40126, Italy.
| | - Abdelmalek Bouraiou
- Equipe de Synthèse de Molécules à Objectif Thérapeutique, Laboratoire des Produits Naturels d'Origine Végétale et de Synthèse Organique (PHYSYNOR), Université des frères Mentouri, Campus de Chaabat-Ersas, Constantine 25000, Algeria.
| | - Vincenza Andrisano
- Department for Life Quality Studies, University of Bologna, Corso d'Augusto, 237, Rimini 47921, Italy.
| | - Helene Martin
- Laboratoire de Toxicologie Cellulaire, EA 4267, Univ. Bourgogne Franche-Comté, 19, rue Ambroise Paré, Besançon Cedex 25030, France.
| | - Alexandre Bonet
- Laboratoire de Toxicologie Cellulaire, EA 4267, Univ. Bourgogne Franche-Comté, 19, rue Ambroise Paré, Besançon Cedex 25030, France.
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Biología, Ciencias Ambientales y Química, Universidad de Alcalá, Ctra. Barcelona, Km. 33.5, Alcalá de Henares 28817, Spain.
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Biología, Ciencias Ambientales y Química, Universidad de Alcalá, Ctra. Barcelona, Km. 33.5, Alcalá de Henares 28817, Spain.
| | - Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain.
| | - Ali Belfaitah
- Equipe de Synthèse de Molécules à Objectif Thérapeutique, Laboratoire des Produits Naturels d'Origine Végétale et de Synthèse Organique (PHYSYNOR), Université des frères Mentouri, Campus de Chaabat-Ersas, Constantine 25000, Algeria.
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain.
| |
Collapse
|
23
|
Benarous K, Bombarda I, Iriepa I, Moraleda I, Gaetan H, Linani A, Tahri D, Sebaa M, Yousfi M. Harmaline and hispidin from Peganum harmala and Inonotus hispidus with binding affinity to Candida rugosa lipase: In silico and in vitro studies. Bioorg Chem 2015; 62:1-7. [DOI: 10.1016/j.bioorg.2015.06.005] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Revised: 06/21/2015] [Accepted: 06/26/2015] [Indexed: 12/26/2022]
|
24
|
Bautista-Aguilera OM, Esteban G, Chioua M, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Soriano E, Samadi A, Unzeta M, Marco-Contelles J. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug Des Devel Ther 2014; 8:1893-910. [PMID: 25378907 PMCID: PMC4207550 DOI: 10.2147/dddt.s69258] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids (DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential treatment of Alzheimer’s disease (AD) is reported. The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD. DPH14 (Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration [IC50] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC50 =600±80 nM) was 318-fold more potent for the inhibition of AChE, and 1.3-fold less potent for the inhibition of BuChE than the reference compound ASS234. DPH14 is a potent human recombinant BuChE (hBuChE) inhibitor, in the same range as DPH12 or DPH16, but 13.1-fold less potent than DPH15 for the inhibition of human recombinant AChE (hAChE). Compared with donepezil, DPH14 is almost equipotent for the inhibition of hAChE, and 8.8-fold more potent for hBuChE. Concerning human monoamine oxidase (hMAO) A inhibition, only DPH9 and 5 proved active, compound DPH9 being the most potent (IC50 [MAO A] =5,700±2,100 nM). For hMAO B, only DPHs 13 and 14 were moderate inhibitors, and compound DPH14 was the most potent (IC50 [MAO B] =3,950±940 nM). Molecular modeling of inhibitor DPH14 within EeAChE showed a binding mode with an extended conformation, interacting simultaneously with both catalytic and peripheral sites of EeAChE thanks to a linker of appropriate length. Absortion, distribution, metabolism, excretion and toxicity analysis showed that structures lacking phenyl-substituent show better druglikeness profiles; in particular, DPHs13–15 showed the most suitable absortion, distribution, metabolism, excretion and toxicity properties. Novel donepezil-pyridyl hybrid DPH14 is a potent, moderately selective hAChE and selective irreversible hMAO B inhibitor which might be considered as a promising compound for further development for the treatment of AD.
Collapse
Affiliation(s)
- Oscar M Bautista-Aguilera
- Laboratory of Medicinal Chemistry (Institute of General Organic Chemistry [IQOG], National Research Council [CSIC]), Madrid, Spain
| | - Gerard Esteban
- Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Autonomous Barcelona University, Barcelona, Spain
| | - Mourad Chioua
- Laboratory of Medicinal Chemistry (Institute of General Organic Chemistry [IQOG], National Research Council [CSIC]), Madrid, Spain
| | - Katarina Nikolic
- Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Danica Agbaba
- Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Ignacio Moraleda
- Department of Organic Chemistry, Faculty of Pharmacy, University of Alcalá, Ctra Barcelona, Alcalá de Henares, Spain
| | - Isabel Iriepa
- Department of Organic Chemistry, Faculty of Pharmacy, University of Alcalá, Ctra Barcelona, Alcalá de Henares, Spain
| | - Elena Soriano
- Synthesis, and Structure of Organic Compounds (SEPCO) (IQOG, CSIC), Madrid, Spain
| | - Abdelouahid Samadi
- Laboratory of Medicinal Chemistry (Institute of General Organic Chemistry [IQOG], National Research Council [CSIC]), Madrid, Spain
| | - Mercedes Unzeta
- Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Autonomous Barcelona University, Barcelona, Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (Institute of General Organic Chemistry [IQOG], National Research Council [CSIC]), Madrid, Spain
| |
Collapse
|
25
|
Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, Iriepa I, Samadi A, Youdim MBH, Romero A, Soriano E, Herrero R, Fernández Fernández AP, Ricardo-Martínez-Murillo, Marco-Contelles J, Unzeta M. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur J Med Chem 2014; 80:543-61. [PMID: 24813882 DOI: 10.1016/j.ejmech.2014.04.078] [Citation(s) in RCA: 110] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 04/24/2014] [Accepted: 04/26/2014] [Indexed: 12/15/2022]
Abstract
The synthesis, biochemical evaluation, ADMET, toxicity and molecular modeling of novel multi-target-directed Donepezil + Propargylamine + 8-Hydroxyquinoline (DPH) hybrids 1-7 for the potential prevention and treatment of Alzheimer's disease is described. The most interesting derivative was racemic α-aminotrile4-(1-benzylpiperidin-4-yl)-2-(((8-hydroxyquinolin-5-yl)methyl)(prop-2-yn-1-yl)amino) butanenitrile (DPH6) [MAO A (IC50 = 6.2 ± 0.7 μM; MAO B (IC50 = 10.2 ± 0.9 μM); AChE (IC50 = 1.8 ± 0.1 μM); BuChE (IC50 = 1.6 ± 0.25 μM)], an irreversible MAO A/B inhibitor and mixed-type AChE inhibitor with metal-chelating properties. According to docking studies, both DPH6 enantiomers interact simultaneously with the catalytic and peripheral site of EeAChE through a linker of appropriate length, supporting the observed mixed-type AChE inhibition. Both enantiomers exhibited a relatively similar position of both hydroxyquinoline and benzyl moieties with the rest of the molecule easily accommodated in the relatively large cavity of MAO A. For MAO B, the quinoline system was hosted at the cavity entrance whereas for MAO A this system occupied the substrate cavity. In this disposition the quinoline moiety interacted directly with the FAD aromatic ring. Very similar binding affinity values were also observed for both enantiomers with ChE and MAO enzymes. DPH derivatives exhibited moderate to good ADMET properties and brain penetration capacity for CNS activity. DPH6 was less toxic than donepezil at high concentrations; while at low concentrations both displayed a similar cell viability profile. Finally, in a passive avoidance task, the antiamnesic effect of DPH6 was tested on mice with experimentally induced amnesia. DPH6 was capable to significantly decrease scopolamine-induced learning deficits in healthy adult mice.
Collapse
Affiliation(s)
- Li Wang
- Division of Chemistry and Biotechnology, Graduate School of Natural Science and Technology, Okayama University, 3.1.1 Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
| | - Gerard Esteban
- Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - Masaki Ojima
- Division of Chemistry and Biotechnology, Graduate School of Natural Science and Technology, Okayama University, 3.1.1 Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
| | | | - Tsutomu Inokuchi
- Division of Chemistry and Biotechnology, Graduate School of Natural Science and Technology, Okayama University, 3.1.1 Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871 Alcalá de Henares, Madrid, Spain
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871 Alcalá de Henares, Madrid, Spain
| | - Abdelouahid Samadi
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Moussa B H Youdim
- Eve Topf Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion-Faculty of Medicine, Haifa 31096, Israel
| | - Alejandro Romero
- Departamento de Toxicología y Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - Elena Soriano
- SEPCO, IQOG (CSIC), Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Raquel Herrero
- Neurovascular Research Group, Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal (CSIC) Av. Doctor Arce 37, 28002 Madrid, Spain
| | - Ana Patricia Fernández Fernández
- Neurovascular Research Group, Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal (CSIC) Av. Doctor Arce 37, 28002 Madrid, Spain
| | - Ricardo-Martínez-Murillo
- Neurovascular Research Group, Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal (CSIC) Av. Doctor Arce 37, 28002 Madrid, Spain
| | - José Marco-Contelles
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Mercedes Unzeta
- Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
| |
Collapse
|
26
|
Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur J Med Chem 2014; 75:82-95. [PMID: 24530494 DOI: 10.1016/j.ejmech.2013.12.028] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 12/11/2013] [Accepted: 12/22/2013] [Indexed: 01/21/2023]
Abstract
The design, synthesis, and pharmacological evaluation of donepezil-indolyl based amines 7-10, amides 12-16, and carboxylic acid derivatives 5 and 11, as multipotent ASS234 analogs, able to inhibit simultaneously cholinesterase (ChE) and monoamine oxidase (MAO) enzymes for the potential treatment of Alzheimer's disease (AD), is reported. Theoretical studies using 3D-Quantitative Structure-Activity Relationship (3D-QSAR) was used to define 3D-pharmacophores for inhibition of MAO A/B, AChE, and BuChE enzymes. We found that, in general, and for the same substituent, amines are more potent ChE inhibitors (see compounds 12, 13 versus 7 and 8) or equipotent (see compounds 14, 15 versus 9 and 10) than the corresponding amides, showing a clear EeAChE inhibition selectivity. For the MAO inhibition, amides were not active, and among the amines, compound 14 was totally MAO A selective, while amines 15 and 16 were quite MAO A selective. Carboxylic acid derivatives 5 and 11 showed a multipotent moderate selective profile as EeACE and MAO A inhibitors. Propargylamine 15 [N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)prop-2-yn-1-amine] resulted in the most potent hMAO A (IC50 = 5.5 ± 1.4 nM) and moderately potent hMAO B (IC50 = 150 ± 31 nM), EeAChE (IC50 = 190 ± 10 nM), and eqBuChE (IC50 = 830 ± 160 nM) inhibitor. However, the analogous N-allyl and the N-morpholine derivatives 16 and 14 deserve also attention as they show an attractive multipotent profile. To sum up, donepezil-indolyl hybrid 15 is a promising drug for further development for the potential prevention and treatment of AD.
Collapse
Affiliation(s)
| | - Gerard Esteban
- Departament de Bioquímica i Biología Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - Irene Bolea
- Departament de Bioquímica i Biología Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - Katarina Nikolic
- Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Danica Agbaba
- Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
| | - Ignacio Moraleda
- Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Alcalá, Ctra. Barcelona, Km. 33.5, 28817 Alcalá de Henares, Spain
| | - Isabel Iriepa
- Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Alcalá, Ctra. Barcelona, Km. 33.5, 28817 Alcalá de Henares, Spain
| | - Abdelouahid Samadi
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Elena Soriano
- SEPCO, (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Mercedes Unzeta
- Departament de Bioquímica i Biología Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - José Marco-Contelles
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
| |
Collapse
|
27
|
Samadi A, de la Fuente Revenga M, Pérez C, Iriepa I, Moraleda I, Rodríguez-Franco MI, Marco-Contelles J. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 2013; 67:64-74. [PMID: 23838422 DOI: 10.1016/j.ejmech.2013.06.021] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 05/31/2013] [Accepted: 06/04/2013] [Indexed: 12/30/2022]
Abstract
6-Chloro-pyridonepezils are chloropyridine-donepezil hybrids designed by combining the N-benzylpiperidine moiety present in donepezil with the 2-chloropyridine-3,5-dicarbonitrile heterocyclic ring system, both connected by an appropriate polymethylene linker. 6-Chloro-pyridonepezils1-8 were prepared by reaction of 2,6-dichloro-4-phenylpyridine-3,5-dicarbonitrile (13) [or 2,6-dichloropyridine-3,5-dicarbonitrile (14)] with suitable 2-(1-benzylpiperidin-4-yl)alkylamines (9-12). The biological evaluation showed that these new compounds are cholinesterase inhibitors, in the submicromolar range, one of them (6) being a potent hBuChE inhibitor (IC50 = 0.47 ± 0.08 μM). 6-Chloro-pyridonepezils4, 7 and 8 are potent hAChE inhibitors showing IC50 in the 0.013-0.054 μM range. Particularly, 6-chloro-pyridonepezil8 is 625-fold more selective for hAChE than for hBuChE and compared to donepezil is equipotent for the inhibition of hAChE. Molecular modeling investigation on 6-chloro-pyridonepezils4, 6-8 supports its dual AChE inhibitory profile, by binding simultaneously at the catalytic active and at peripheral anionic sites of the enzyme. The in vitro Blood Brain Barrier (BBB) and theoretical ADME analysis of 6-chloro-pyridonepezils1-8 have been carried out. Overall, compound 8, is a permeable potent and selective dual AChEI that can be considered as a good candidate with potential impact for further pharmacological development in Alzheimer's therapy.
Collapse
Affiliation(s)
- Abdelouahid Samadi
- Laboratorio de Química Médica, Instituto de Química Orgánica General (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
28
|
Amorós I, Dolz-Gaitón P, Gómez R, Matamoros M, Barana A, de la Fuente MG, Núñez M, Pérez-Hernández M, Moraleda I, Gálvez E, Iriepa I, Tamargo J, Caballero R, Delpón E. Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore. Biochem Pharmacol 2013; 86:267-78. [PMID: 23648307 DOI: 10.1016/j.bcp.2013.04.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 04/23/2013] [Accepted: 04/25/2013] [Indexed: 11/24/2022]
Abstract
Human cardiac inward rectifier current (IK1) is generated by Kir2.x channels. Inhibition of IK1 could offer a useful antiarrhythmic strategy against fibrillatory arrhythmias. Therefore, elucidation of Kir2.x channels pharmacology, which still remains elusive, is mandatory. We characterized the electrophysiological and molecular basis of the inhibition produced by the antiarrhythmic propafenone of the current generated by Kir2.x channels (IKir2.x) and the IK1 recorded in human atrial myocytes. Wild type and mutated human Kir2.x channels were transiently transfected in CHO and HEK-293 cells. Macroscopic and single-channel currents were recorded using the patch-clamp technique. At concentrations >1μM propafenone inhibited IKir2.x the order of potency being Kir2.3∼IK1>Kir2.2>Kir2.1 channels. Blockade was irrespective of the extracellular K(+) concentration whereas markedly increased when the intracellular K(+) concentration was decreased. Propafenone decreased inward rectification since at potentials positive to the K(+) equilibrium potential propafenone-induced block decreased in a voltage-dependent manner. Importantly, propafenone favored the occurrence of subconductance levels in Kir2.x channels and decreased phosphatidylinositol 4,5-bisphosphate (PIP2)-channel affinity. Blind docking and site-directed mutagenesis experiments demonstrated that propafenone bound Kir2.x channels at the cytoplasmic domain, close to, but not in the pore itself, the binding site involving two conserved Arg residues (residues 228 and 260 in Kir2.1). Our results suggested that propafenone incorporated into the cytoplasmic domain of the channel in such a way that it decreased the net negative charge sensed by K(+) ions and polyamines which, in turn, promotes the appearance of subconductance levels and the decrease of PIP2 affinity of the channels.
Collapse
Affiliation(s)
- Irene Amorós
- Department of Pharmacology, School of Medicine, Universidad Complutense, 28040 Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Silva D, Chioua M, Samadi A, Agostinho P, Garção P, Lajarín-Cuesta R, de los Ríos C, Iriepa I, Moraleda I, Gonzalez-Lafuente L, Mendes E, Pérez C, Rodríguez-Franco MI, Marco-Contelles J, Carmo Carreiras M. Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity. ACS Chem Neurosci 2013; 4:547-65. [PMID: 23379636 DOI: 10.1021/cn300178k] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The synthesis, molecular modeling, and pharmacological analysis of phenoxyalkylamino-4-phenylnicotinates (2-7), phenoxyalkoxybenzylidenemalononitriles (12, 13), pyridonepezils (14-18), and quinolinodonepezils (19-21) are described. Pyridonepezils 15-18 were found to be selective and moderately potent regarding the inhibition of hAChE, whereas quinolinodonepezils 19-21 were found to be poor inhibitors of hAChE. The most potent and selective hAChE inhibitor was ethyl 6-(4-(1-benzylpiperidin-4-yl)butylamino)-5-cyano-2-methyl-4-phenylnicotinate (18) [IC(50) (hAChE) = 0.25 ± 0.02 μM]. Pyridonepezils 15-18 and quinolinodonepezils 20-21 are more potent selective inhibitors of EeAChE than hAChE. The most potent and selective EeAChE inhibitor was ethyl 6-(2-(1-benzylpiperidin-4-yl)ethylamino)-5-cyano-2-methyl-4-phenylnicotinate (16) [IC(50) (EeAChE) = 0.0167 ± 0.0002 μM], which exhibits the same inhibitory potency as donepezil against hAChE. Compounds 2, 7, 13, 17, 18, 35, and 36 significantly prevented the decrease in cell viability caused by Aβ(1-42). All compounds were effective in preventing the enhancement of AChE activity induced by Aβ(1-42). Compounds 2-7 caused a significant reduction whereas pyridonepezils 17 and 18, and compound 16 also showed some activity. The pyrazolo[3,4-b]quinolines 36 and 38 also prevented the upregulation of AChE induced by Aβ(1-42). Compounds 2, 7, 12, 13, 17, 18, and 36 may act as antagonists of voltage sensitive calcium channels, since they significantly prevented the Ca(2+) influx evoked by KCl depolarization. Docking studies show that compounds 16 and 18 adopted different orientations and conformations inside the active-site gorges of hAChE and hBuChE. The structural and energetic features of the 16-AChE and 18-AChE complexes compared to the 16-BuChE and 18-BuChE complexes account for a higher affinity of the ligand toward AChE. The present data indicate that compounds 2, 7, 17, 18, and 36 may represent attractive multipotent molecules for the potential treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Daniel Silva
- Research Institute for Medicines and Pharmaceutical
Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de
la Cierva 3, 28006-Madrid, Spain
| | - Mourad Chioua
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de
la Cierva 3, 28006-Madrid, Spain
| | - Abdelouahid Samadi
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de
la Cierva 3, 28006-Madrid, Spain
| | - Paula Agostinho
- Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
- Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - Pedro Garção
- Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
- Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - Rocío Lajarín-Cuesta
- Instituto Teófilo Hernando, Fundación
de Investigación Biomédica, Hospital Universitario de la Princesa, C/Diego de Léon, 62, 28006-Madrid,
Spain
| | - Cristobal de los Ríos
- Instituto Teófilo Hernando, Fundación
de Investigación Biomédica, Hospital Universitario de la Princesa, C/Diego de Léon, 62, 28006-Madrid,
Spain
| | - Isabel Iriepa
- Departamento de Química
Orgánica. Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares,
Madrid, Spain
| | - Ignacio Moraleda
- Departamento de Química
Orgánica. Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871, Alcalá de Henares,
Madrid, Spain
| | - Laura Gonzalez-Lafuente
- Instituto Teófilo Hernando, Fundación
de Investigación Biomédica, Hospital Universitario de la Princesa, C/Diego de Léon, 62, 28006-Madrid,
Spain
| | - Eduarda Mendes
- Research Institute for Medicines and Pharmaceutical
Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Concepción Pérez
- Instituto
de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan
de la Cierva 3, 28006-Madrid, Spain
| | - María Isabel Rodríguez-Franco
- Instituto
de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan
de la Cierva 3, 28006-Madrid, Spain
| | - José Marco-Contelles
- Laboratorio de Química Médica (IQOG, CSIC), C/Juan de
la Cierva 3, 28006-Madrid, Spain
| | - M. Carmo Carreiras
- Research Institute for Medicines and Pharmaceutical
Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| |
Collapse
|
30
|
Samadi A, Estrada M, Pérez C, Rodríguez-Franco MI, Iriepa I, Moraleda I, Chioua M, Marco-Contelles J. Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling. Eur J Med Chem 2012; 57:296-301. [PMID: 23078965 DOI: 10.1016/j.ejmech.2012.09.030] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2012] [Revised: 09/20/2012] [Accepted: 09/24/2012] [Indexed: 11/17/2022]
Abstract
The synthesis, biological assessment and molecular modeling of new pyridonepezils1-8, able to inhibit human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), are described. The new compounds have been designed as hybrids resulting from a conjunctive approach that combines the N-benzylpiperidine moiety, present in donepezil, and the 2-amino-6-chloropyridine heterocyclic ring system, connected by an appropriate polymethylene linker. Compounds 1-8 were prepared by reaction of 2-amino-6-chloro-4-phenylpyridine-3,5-dicarbonitrile (13) [or 2-amino-6-chloropyridine-3,5-dicarbonitrile (14)] with 2-(1-benzylpiperidin-4-yl)alkylamines (9-12). The biological evaluation of molecules 1-8 showed that compounds 1-6 are potent AChE inhibitors, in the submicromolar, while compounds 7 and 8 are on the nanomolar range, the most potent, 2-amino-6-((3-(1-benzylpiperidin-4-yl)propyl)amino)pyridine-3,5-dicarbonitrile (7), showing a IC(50) (hAChE) = 9.4 ± 0.4 nM. Inhibitors 2-8 are permeable as determined in the PAMPA assay. Compared to donepezil, compound 7 is in the same range of inhibitory activity for hAChE, and 703-fold more selective for hAChE than for hBuChE. Molecular modeling investigation on pyridonepezil7 supports its dual AChE inhibitory profile, binding simultaneously at the catalytic active and at peripheral anionic sites of the enzyme. The theoretical ADME analysis of pyridonepezils1-8 has been carried out. Overall, compound 7, a potent and selective dual AChEI, can be considered as a candidate with potential impact for further pharmacological development in Alzheimer's therapy.
Collapse
Affiliation(s)
- Abdelouahid Samadi
- Laboratorio de Química Médica, Instituto de Química Orgánica General (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Maalej E, Chabchoub F, Oset-Gasque MJ, Esquivias-Pérez M, González MP, Monjas L, Pérez C, de los Ríos C, Rodríguez-Franco MI, Iriepa I, Moraleda I, Chioua M, Romero A, Marco-Contelles J, Samadi A. Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 2012; 54:750-63. [DOI: 10.1016/j.ejmech.2012.06.038] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Revised: 06/11/2012] [Accepted: 06/13/2012] [Indexed: 01/28/2023]
|
32
|
Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur J Med Chem 2012; 52:251-62. [DOI: 10.1016/j.ejmech.2012.03.022] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 03/12/2012] [Accepted: 03/13/2012] [Indexed: 10/28/2022]
|
33
|
Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Marco-Contelles J. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer’s disease. Eur J Med Chem 2011; 46:4665-8. [DOI: 10.1016/j.ejmech.2011.05.048] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2011] [Revised: 05/16/2011] [Accepted: 05/19/2011] [Indexed: 01/25/2023]
|
34
|
Bartolini M, Pistolozzi M, Andrisano V, Egea J, López MG, Iriepa I, Moraleda I, Gálvez E, Marco-Contelles J, Samadi A. Chemical and Pharmacological Studies on Enantiomerically Pure p-Methoxytacripyrines, Promising Multi-Target-Directed Ligands for the Treatment of Alzheimer’s Disease. ChemMedChem 2011; 6:1990-7. [DOI: 10.1002/cmdc.201100239] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 07/22/2011] [Indexed: 11/11/2022]
|
35
|
de Los Ríos C, Egea J, Marco-Contelles J, León R, Samadi A, Iriepa I, Moraleda I, Gálvez E, García AG, López MG, Villarroya M, Romero A. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J Med Chem 2010; 53:5129-43. [PMID: 20575555 DOI: 10.1021/jm901902w] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most tacrine derivatives previously synthesized in our laboratory. The compounds presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A. Moreover, compound 14 (ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate) also caused protection in cells stressed with okadaic acid (OA) or amyloid beta 1-42 peptide (Abeta(1-42)). Interestingly, compound 14 prevented the OA-induced PP2A inhibition, one of the enzymes implicated in tau dephosphorylation. This compound also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices. Because these stressors caused neuronal damage related to physiopathological hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compound 14 deserves further in vivo studies in AD models to test its therapeutic potential in this disease.
Collapse
Affiliation(s)
- Cristóbal de Los Ríos
- Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Instituto Teofilo Hernando, Universidad Autonoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|